瑞舒伐他汀对急性冠脉综合征患者IL-6、GMP-140、BNP及心功能的影响

目的 观察瑞舒伐他汀治疗急性冠脉综合征患者白细胞介素-6（IL-6）、血浆α-颗粒膜蛋白（GMP-140）、脑钠素（BNP）和心功能的变化.方法 80例急性冠脉综合征患者随机分为两组,对照组40例给予常规治疗;治疗组40例在对照组治疗的基础上加用瑞舒伐他汀口服.两组疗程均为32周.结果 治疗32周治疗组血清IL-6、 GMP-140和BNP显著低于对照组（P＜0.01）,左室射血分数（LVEF）明显改善（P＜0.01）,对照组无明显变化.结论 瑞舒伐他汀治疗急性冠脉综合症患者可以使血清IL-6、GMP-140和BNP水平显著下降,减轻炎症反应,抑制血小板活化,稳定动脉粥样硬化斑块,改善心功能.

Effects of rosuvastatin on serum IL-6,GMP-140,BNP and heart function on treatment of acute coronary syndromes

Objective To observe the clinical effect of rosuvastatin plasma IL-6, GMP-140, BNP levels and heart function in patients with acute eoronary syndromes. Methods 80 cases of acute eoronary syndromes patients were randomly divided into two groups.40 ea- ses in control group were given conventional treatment while 40 cases in treatment group were given oral rosuvastatin based on the con- trol group treatment. Both groups were treated for 32 weeks. Results After the treatment, in treatment group, serum IL-6 、GMP-140 and BNP were significantly lower than those in the control group（P 〈 0.01）. LVEF was increased in treatment group,while these were not significant change in treatment group. Conclusions Rosuvastatin treatment of acute eoronat7 syndromes can have a significant re- duction in sermn IL-6, GMP-140 and BNP level, reduce inflammation reaction, inhibit activation of platelet, stable atheroselerotie plaque, and improve heart function.